Oracle’s March 10 Financial Results: Could This Trigger a Market Misvaluation?

Analyst Opinions Diverge on Oracle’s Short-Term Prospects

Analysts are currently divided on Oracle’s immediate outlook. DA Davidson recently upgraded Oracle to a Buy rating, setting a price target of $180. In contrast, RBC lowered its target to $160 and kept a “sector perform” rating. This disagreement highlights a central market debate: does OpenAI’s high rate of cash consumption pose a short-term risk, or could it become a long-term advantage for OracleORCL+2.57%?

DA Davidson’s optimistic view is based on OpenAI’s more transparent spending plans, which they believe will help OpenAI fulfill its commitments to Oracle. This, in their opinion, alleviates the main concern weighing on Oracle’s stock. On the other hand, RBC remains cautious, doubting OpenAI’s ability to secure enough funding. Their downgrade reflects worries that the financial burden of supporting OpenAI’s AI expansion could continue to pressure Oracle’s shares.

This debate is unfolding as Oracle’s stock has experienced a sharp correction. Shares have dropped over 23% in 2026 and are down more than 54% since mid-September, when the $300 billion deal was first announced. Such a steep decline suggests that much of the perceived risk is already reflected in the price, potentially setting up an opportunity if positive developments around OpenAI’s funding emerge. The next major event is Oracle’s earnings report on March 10, which could provide crucial clarity.

Financial Implications: Assessing Oracle’s OpenAI Exposure

The key issue for Oracle’s valuation is whether the OpenAI partnership represents a hidden risk or a delayed revenue source. While the recent market selloff points to the former, the financial data tells a more complex story. Oracle currently trades at a P/E ratio of 26.68, below its decade-long average of 28.38. Despite this, the stock is still trading at a notable discount, reflecting a 23% drop in 2026. This gap between a reasonable valuation and a depressed share price underscores the potential for mispricing.

RSI Oversold Long-Only Strategy Backtest

• Entry Condition: Buy when RSI(14) is below 30 and the price is above the 50-day simple moving average (SMA).
• Exit Condition: Sell when RSI(14) exceeds 70, after 15 trading days, or if the position hits a 10% gain or a 5% loss.
• Backtest Period: March 4, 2025 to March 4, 2026
• Asset: ORCL
• Risk Controls:
  • Take-Profit: 10%
  • Stop-Loss: 5%
  • Maximum Hold: 15 days

Backtest Results

• Strategy Return: 0%
• Annualized Return: 0%
• Maximum Drawdown: 0%
• Win Rate: 0%

Evaluating the OpenAI Deal’s Impact

The fate of Oracle’s partnership with OpenAI depends entirely on OpenAI’s ability to secure new funding. Concerns about heavy cash outflows and uncertain financing have contributed to Oracle’s stock decline. RBC’s downgrade specifically points to the risk that OpenAI’s financial challenges could drag on Oracle’s performance.

Nonetheless, Oracle’s main business remains resilient. Despite the uncertainty surrounding OpenAI, Oracle’s shares have outperformed the broader market recently. This suggests investors are distinguishing between the risks tied to OpenAI and Oracle’s core operations. The company’s cloud and database segments continue to grow, albeit at a steady rather than rapid pace. The current valuation discount may reflect more of a speculative bet against OpenAI than any real weakness in Oracle’s underlying business.

Ultimately, the risks associated with OpenAI are already factored into Oracle’s share price. The P/E ratio indicates the stock isn’t excessively valued, but the 23% drop from its 52-week high and rising credit default swap (CDS) spreads show investors are demanding a premium for the perceived risk. For investors looking for tactical opportunities, this creates a binary scenario: if OpenAI’s funding and spending plans become more certain, Oracle’s stock could rebound quickly. If not, the discount could widen further. The upcoming March 10 earnings announcement will be a pivotal moment for this narrative.

Valuation Outlook: Weighing Risks and Rewards

Market expectations for Oracle are split between two extremes. The average analyst target of $286.94 suggests substantial upside, but this figure is influenced by optimistic projections from firms like Oppenheimer ($185) and Scotiabank ($220). RBC’s more conservative $160 target, however, implies the stock could stagnate or fall further if OpenAI’s funding remains unresolved. This divergence sets the stage for a high-impact event.

If the OpenAI partnership succeeds, Oracle could benefit from renewed enthusiasm around its AI capabilities. Recent clarity around OpenAI’s spending is encouraging, and if OpenAI secures additional funding and demonstrates a path to profitability, Oracle’s role as a critical infrastructure provider would be reinforced. This could drive the stock closer to the upper end of analyst estimates. Oracle’s relatively low exposure to AI disruption and its underrepresentation in portfolios could further boost positive momentum.

However, if OpenAI continues to burn through cash without securing new capital, the worst-case scenario could unfold. This might force a renegotiation of the $300 billion agreement or even lead to a write-down. Elevated CDS spreads already indicate that bond investors are concerned about default risk. For Oracle, this would mean an even steeper discount as speculative fears become tangible financial problems.

The Q3 FY2026 earnings release on March 10 is the next major event. Investors will be watching for management’s insights on OpenAI’s financial health and any updates on the partnership. Positive developments could trigger a rally, while ongoing uncertainty would likely reinforce the market’s cautious approach. The risk/reward equation is clear: the stock is priced for trouble, but a resolution could unlock significant upside.

Key Catalysts and Risks to Monitor

Oracle’s near-term trajectory will be shaped by several critical signals. While the March 10 earnings report is the most immediate catalyst, investors should also pay attention to other developments that could confirm or challenge the current market view.

• OpenAI and Investor Announcements: The market’s anxiety stems from uncertainty about OpenAI’s funding and expenditures. While recent reports of clarified plans are encouraging, they haven’t been enough to halt the stock’s decline. Watch for official announcements of new funding or a credible path to profitability. Any signs of financial distress, such as further delays or changes in spending, could intensify selling pressure. Conversely, progress could spark a relief rally.
• Insider and Institutional Activity: Insiders have sold approximately 72,223 shares worth $13.7 million in the past three months. While this may be routine, a persistent trend of executive selling would be concerning. Similarly, shifts in institutional ownership after earnings could signal changing sentiment among large investors.
• March 10 Earnings Report: This earnings call will be closely watched for updates on the OpenAI partnership and Oracle’s own financial stability, especially given its debt levels and cash outflows. Any positive news regarding OpenAI could drive a rally, while continued uncertainty would likely reinforce the market’s cautious stance. Elevated CDS spreads already reflect bondholders’ concerns, making this report a crucial test.